{
  "source": "PA-Med-Nec-Nucala.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2172-12\nProgram Prior Authorization/Medical Necessity\nMedications *Nucala® (mepolizumab)\n* This program applies to the prefilled autoinjector and prefilled syringe\nformulations.\nP&T Approval Date 8/2019, 4/2020, 8/2020, 3/2021, 6/2021, 9/2021, 11/2021, 2/2022,\n6/2022, 6/2023, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nNucala (mepolizumab) is an interleukin-5 receptor antagonist indicated for add-on maintenance\ntreatment of patients aged 6 years and older with severe asthma and with an eosinophilic\nphenotype, for add-on maintenance treatment of adult patients 18 years and older with chronic\nrhinosinusitis with nasal polyps (CRSwNP), the treatment of adult patients with eosinophilic\ngranulomatosis with polyangiitis (EGPA), and the treatment of adult and pediatric patients aged\n12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable\nnon-hematologic secondary cause1.\nLimitations of use:\nNucala is not for relief of acute bronchospasm of status asthmaticus.\n2. Coverage Criteriaa:\nA. Eosinophilic granulomatosis with polyangiitis (EGPA)\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nEGPA\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy as\ndemonstrated by at least one of the following:\ni. Reduction in the frequency and/or severity of relapses\nii. Reduction or discontinuation of doses of corticosteroids and/or\nimmunosuppressant\niii. Disease remission\niv. Reduction in severity or frequency of EGPA-related symptoms\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)",
    " 2024 UnitedHealthcare Services, Inc.\n1\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(d) Prescribed by one of the following:\ni. Pulmonologist\nii. Rheumatologist\niii. Allergist\niv. Immunologist\n-OR-\n(2) All of the following:\n(a) Diagnosis of relapsing or refractory EGPA as defined by all of the\nfollowing:\ni. Diagnosis of EGPA\n-AND-\nii. Past medical history or presence of asthma\n-AND-\niii. Presence of at least two of the following characteristics typical of\nEGPA:\n• Histopathological evidence of:\n Eosiophilic vasculitis\n Pervascular eosinophilic infiltration\n Eosinophil-rich granulomatous inflammation\n• Neuropathy, mono or poly (motor deficit or nerve\nconductionabnormality)\n• Pulmonary infiltrates, non-fixed\n• Sino-nasal abnormality\n• Cardiomyopathy (established by echocardiography or MRI)\n• Glomerulonephritis (hematuria, red cell casts, proteinuria)\n• Alveolar hemorrhage\n• Palpable purpura\n• Anti-neutrophil cytoplasmic antibody (ANCA) positive\n© 2024 UnitedHealthcare Services, Inc.\n2\n-AND-\niv. History of relapsing or refractory disease defined as one of the\nfollowing:\n• Relapsing disease as defined as a past history (within the past 2\nyears) of at least one EGPA relapse (requiring additional or dose\nescalation of corticosteroids or immunosuppressant, or\nhospitalization)\n• Refractory disease as defined as failure to attain remission within\nthe prior 6 months following induction treatment with standard\ntherapy regimens\n-AND-\n(b) Patient is currently taking standard therapy [i.e., systemic glucocorticoids (e.g.,\nprednisone, methylprednisolone) with or without immunosuppressive therapy\n(e.g., cyclophosphamide, rituximab)]\n-AND-\n(c) Patient is not receiving Nuca",
    "rd therapy [i.e., systemic glucocorticoids (e.g.,\nprednisone, methylprednisolone) with or without immunosuppressive therapy\n(e.g., cyclophosphamide, rituximab)]\n-AND-\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab),\nFasenra(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(d) Prescribed by one of the following:\ni. Pulmonologist\nii. Rheumatologist\niii. Allergist\niv. Immunologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Nucala therapy as demonstrated\nby at least one of the following:\n(a) Reduction in the frequency and/or severity of relapses\n(b) Reduction or discontinuation of doses of corticosteroids and/or\nimmunosuppressant\n© 2024 UnitedHealthcare Services, Inc.\n3\n(c) Disease remission\n(d) Reduction in severity or frequency of EGPA-related symptoms\n-AND-\n(2) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\nB. Severe Asthma\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy as\ndemonstrated by at least one of the following:\ni. Reduction in the frequency",
    "authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy as\ndemonstrated by at least one of the following:\ni. Reduction in the frequency of exacerbations\nii. Decreased utilization of rescue medications\niii. Increase in percent predicted FEV1 from pretreatment baseline\niv. Reduction in severity or frequency of asthma-related symptoms\n(e.g., wheezing, shortness of breath, coughing, etc.)\nv. Reduction in oral corticosteroid requirements\n-AND-\n(c) Nucala is being used in combination with an inhaled corticosteroid (ICS)-\ncontaining maintenance medication [e.g., Advair/AirDuo\n(fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol),\nSymbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n4\n(d) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE-therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Pulmonologist\nii. Allergist\niii. Immunologist\n-OR-\n(2) All of the following:\n(a) Diagnosis of severe asthma\n-AND-\n(b) Classification of asthma as uncontrolled or inadequately controlled as\ndefined by at least one of the following:\ni. Poor symptom control (e.g., Asthma Control Questionnaire [ACQ]\nscore consistently greater than 1.5 or Asthma Control Test [ACT] score\nconsistently less than 20)\nii. Two or more bursts of systemic corticosteroids for at least 3 days each\nin the previous 12 months\niii. Asthma-related emergency treatment (e.g., emergency room visit,\nhospital admission, or unscheduled physician’s office visit for nebulizer\nor other urgent treatment)\niv. Airflow limitation (e.g., after appropriate bronchodilator withhol",
    "(e.g., emergency room visit,\nhospital admission, or unscheduled physician’s office visit for nebulizer\nor other urgent treatment)\niv. Airflow limitation (e.g., after appropriate bronchodilator withhold\nforced expiratory volume in 1 second [FEV1] less than 80% predicted\n[in the face of reduced FEV1/forced vital capacity [FVC] defined as\nless than the lower limit of normal])\nv. Patient is currently dependent on oral corticosteroids for the treatment\nof asthma\n-AND-\n(c) Submission of medical records (e.g., chart notes, laboratory values, etc.)\nconfirming asthma is an eosinophilic phenotype as defined by a baseline\n(pre-treatment) peripheral blood eosinophil level ≥ 150 cells/μL\n© 2024 UnitedHealthcare Services, Inc.\n5\n-AND-\n(d) Nucala will be used in combination with one of the following:\ni. One maximally dosed (appropriately adjusted for age) combination\ninhaled corticosteroid (ICS)/long-acting beta agonist (LABA) [e.g.,\n2\nAdvair/AirDuo Respiclick (fluticasone propionate/salmeterol),\nSymbicort (budesonide/formoterol), Breo Ellipta (fluticasone\nfuroate/vilanterol)]\n-OR-\nii. Combination therapy including both of the following:\n• One maximally dosed (appropriately adjusted for age) ICS\nproduct [e.g., ciclesonide (Alvesco), mometasone furoate\n(Asmanex), beclomethasone dipropionate (QVAR)]\n-AND-\n• One additional asthma controller medication [e.g., LABA -\nolodaterol (Striverdi) or indacaterol (Arcapta); leukotriene\nreceptor antagonist – montelukast (Singulair); theophylline]\n-AND-\n(e) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(f) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reautho",
    "in (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(f) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Nucala therapy as demonstrated\n© 2024 UnitedHealthcare Services, Inc.\n6\nby at least one of the following:\n(a) Reduction in the frequency of exacerbations\n(b) Decreased utilization of rescue medications\n(c) Increase in percent predicted FEV1 from pretreatment baseline\n(d) Reduction in severity or frequency of asthma-related symptoms (e.g.,\nwheezing, shortness of breath, coughing, etc.)\n(e) Reduction in oral corticosteroid requirements\n-AND-\n(2) Nucala is being used in combination with an ICS-containing maintenance\nmedication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta\n(fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy\nEllipta (fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(3) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\nC. Hypereosinophilic Sydrome (HES)\n1. Initial Authorization\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nHES\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy as\ndemonstrated by at least one of the following:\ni. Reduction in frequency of HES flares\nii. Maintenance or reduction in background HES therapy requirements\n-AND-\n© 2024 ",
    "l response to Nucala therapy as\ndemonstrated by at least one of the following:\ni. Reduction in frequency of HES flares\nii. Maintenance or reduction in background HES therapy requirements\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n7\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(d) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Hematologist\niv. Cardiologist\nv. Pulmonologist\n-OR-\n(2) All of the following:\n(a) Diagnosis of HES ≥ 6 months ago\n-AND-\n(b) Both of the following:\ni. There is no identifiable non-hematologic secondary cause of the\npatient’s HES (e.g., drug hypersensitivity, parasitic helminth\ninfection, HIV infection, non-hematologic malignancy)\n-AND-\nii. HES is not FIP1L1-PDGFRα kinase-positive\n-AND-\n(c) Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting both of the following:\ni. Baseline (pre-mepolizumab treatment) blood eosinophil level ≥1000\ncells/µL within the past 4 weeks\n-AND-\nii. Patient is currently receiving a stable dose of background HES therapy\n(e.g., oral corticosteroid, immunosuppressor, or cytotoxic therapy)\n© 2024 UnitedHealthcare Services, Inc.\n8\n-AND-\n(d) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Hematologist\niv. Cardiologist\nv. Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reau",
    "spire\n(tezepelumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Hematologist\niv. Cardiologist\nv. Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Nucala therapy as demonstrated\nby at least one of the following:\ni. Reduction in frequency of HES flares\nii. Maintenance or reduction in background HES therapy requirements\n-AND-\n(2) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\nD. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)\n1. Initial Authorization\n© 2024 UnitedHealthcare Services, Inc.\n9\na. Nucala will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Nucala under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nCRSwNP\n-AND-\n(b) Documentation of positive clinical response to Nucala therapy\n-AND-\n(c) Patient will continue to receive Nucala as add-on maintenance therapy in\ncombination with intranasal corticosteroids (e.g., fluticasone, mometasone,\ntriamcinolone).\n-AND-\n(d) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Otolaryngologist\niv. Pulmonologist\n-OR-\n(2",
    "Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Otolaryngologist\niv. Pulmonologist\n-OR-\n(2) All of the following:\n(a) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) defined by\nall of the following:\ni. Two or more of the following symptoms for longer than 12 weeks\nduration:\n• Nasal mucopurulent discharge\n• Nasal obstruction, blockage, or congestion\n© 2024 UnitedHealthcare Services, Inc.\n10\n• Facial pain, pressure, and/or fullness\n• Reduction or loss of sense of smell\n-AND-\nii. One of the following findings using nasal endoscopy and/or sinus\ncomputed tomography (CT):\n• Purulent mucus or edema in the middle meatus or ethmoid\nregions\n• Polyps in the nasal cavity or the middle meatus\n• Radiographic imaging demonstrating mucosal thickening or\npartial or complete opacification of paranasal sinuses\n-AND-\niii. One of the following:\n• Presence of bilateral nasal polyposis\n• Patient has previously required surgical removal of bilateral\nnasal polyps\n-AND-\niv. One of the following:\n• Patient has required prior sinus surgery\n• Patient has required systemic corticosteroids (e.g., prednisone,\nmethylprednisolone) for CRSwNP in the previous 2 years\n• Patient has been unable to obtain symptom relief after trial of\ntwo of the following classes of agents:\nNasal saline irrigations\no\nIntranasal corticosteroids (e.g., fluticasone, mometasone,\no\ntriamcinolone)\nAntileukotriene agents (e.g., montelukast, zafirlukast,\no\nzileuton)\n-AND-\n(b) Patient will receive Nucala as add-on maintenance therapy in combination\nwith intranasal corticosteroids (e.g., fluticasone, mometasone,\ntriamcinolone)\n-AND-\n(c) Patient is not receiving Nucala in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thym",
    " Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n© 2024 UnitedHealthcare Services, Inc.\n11\n-AND-\n(d) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Otolaryngologist\niv. Pulmonologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Nucala will be approved based on all of the following criterion:\n(1) Documentation of positive clinical response to Nucala therapy\n-AND-\n(2) Patient will continue to receive Nucala as add-on maintenance therapy in\ncombination with intranasal corticosteroids (e.g., fluticasone, mometasone,\ntriamcinolone).\n-AND-\n(3) Patient is not receiving Nucala in combination with any of the following:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra\n(benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n• The single-dose vial is typically covered under the medical benefit. Please refer to the United\nHealthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®, Fasenra®, and\nNuc",
    " place.\n• The single-dose vial is typically covered under the medical benefit. Please refer to the United\nHealthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®, Fasenra®, and\nNucala®)”.\n© 2024 UnitedHealthcare Services, Inc.\n12\n4. References:\n1. Nucala® [package insert]. Philadelphia, PA: GlaxoSmithKline, LLC; March 2023.\n2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition,\nevaluation and treatment of severe asthma. Eur Respir J. 2014 Feb:43(2):343-73.\n3. Institute for Clinical and Economic Review (ICER). Mepolizumab (Nucala®, GlaxoSmithKline\nplc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-\nBased Price Benchmarks. March 14, 2016. Available at http://icer-review.org/material/asthma-\nfinal-report/. Accessed May 2024.\n4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023.\nAvailable at http://www.ginasthma.org. Accessed May 29, 2024.\n5. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, et al. Oral Glucocorticoid-Sparing Effect of\nMepolizumab in Eosinophilic Asthma. New Eng J Med. 2014 Sept:371(13):1189-97.\n6. Parameswaran KN, Dasgupta A, et al. Mepolizumab in COPD with Eosinophilic Bronchitis: A\nRandomized Clinical Trial. Poster session presented at the Annual Meeting of the American\nAcademy of Allergy, Asthma and Immunology, Los Angeles, CA. March 2016.\n7. Centers for Disease Control and Prevention. Asthma. Available at http://www.cdc.gov./asthma/.\nAccessed May 29, 2024.\n8. National Heart, Lung and Blood Institute. Explore Asthma. Available at\nhttp://www.nhlbi.nih.gov. Accessed May 29, 2024.\n9. Hypereosinophilic Syndrome (HES). American Academy of Allergy, Asthma & Immunology.\nAvailable at https://www.aaaai.org. Accessed May 29, 2024.\n10. Roufosse F, Kahn J-E, Rothenberg ME, et. al. Efficacy and safety of mepolizumab in\nhypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial. Journal of Allergy\nand Clinical Immunolo",
    "ufosse F, Kahn J-E, Rothenberg ME, et. al. Efficacy and safety of mepolizumab in\nhypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial. Journal of Allergy\nand Clinical Immunology. September 2020.\n11. Roufosse F, Klion A, Weller P. Hypereosinophilic syndromes: Clinical manifestations,\npathophysiology, and diagnosis. Updated July 22, 2022. Accessed May 29, 2024.\n12. Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and\nrhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6:S22-S209.\n13. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice\nparameter update. Ann Allergy Asthma Immuno. 2014;113:347-385.\n14. Buchheit KM, Holbrook EH.. Chronic rhinosinusitis with nasal polyposis: Management and\nprognosis. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Updated\nAugust 3, 2023. Accessed on May 29, 2024.\n15. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N,\nMayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators.\nMepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-\nblind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Apr 16:S2213-2600(21)00097-\n7. doi: 10.1016/S2213-2600(21)00097-7. Epub ahead of print. PMID: 33872587.\n16. Holbrook EH. Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis.\nUpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Updated August 3, 2023.\nAccessed on May 29, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n13\n17. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the\nclassification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum.\n1990;33(8):1094-1100. doi:10.1002/art.1780330806\n18. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L,\nKhurana S, Knight S, McDonald VM, Morgan RL, Ortega VE,",
    "1990;33(8):1094-1100. doi:10.1002/art.1780330806\n18. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L,\nKhurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T,\nAdcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A,\nDjukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H,\nVitary C, Bush A. Management of severe asthma: a European Respiratory Society/American\nThoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi:\n10.1183/13993003.00588-2019. PMID: 31558662\nProgram Prior Authorization/Notification - Nucala (mepolizumab)\nChange Control\n8/2019 New program.\n4/2020 Updated program to address specific product formulations. Updated\nreferences.\n8/2020 Annual review. Updated background and references.\n3/2021 Updated program to add HES indication. Added limitations of use.\nUpdated references.\n6/2021 Added criteria if patient has been approved and received initial dose of\nNucala directly monitored by a healthcare professional without reaction.\n9/2021 Added coverage criteria for new indication, chronic rhinosinusitis with\nnasal polyps. Updated background and references.\n11/2021 Added coverage criteria for patients established on therapy under\nUnitedHealthcare medical benefit. Removed prescriber requirement for\nreauthorization.\n2/2022 Added Tezspire to list of agents not to be used in combination with\nNucala for all indications. Updated coverage criteria for CRSwNP.\nUpdated references. Added footnote to support FDA labeled first line\nrequirements.\n6/2022 Added pulmonologist to list of appropriate prescribers in section for\npatients established on therapy with Nucala for CRSwNP.\n6/2023 Annual review. Updated examples of standard therapy for EGPA and\nadded examples of oral corticosteroids within Asthma criteria. Updated\nbackground and references.\n7/2023 Updated EGPA standard therapy examples. Updated coverage criteria\nfor severe",
    "erapy for EGPA and\nadded examples of oral corticosteroids within Asthma criteria. Updated\nbackground and references.\n7/2023 Updated EGPA standard therapy examples. Updated coverage criteria\nfor severe asthma to align with GINA & ERS/ATS guidelines.\nAdded/updated examples of ICS-containing maintenance medications,\nremoved requirement that peripheral blood eosinophil level must be\nwithin 6 weeks, and removed bypass of eosinophilic phenotype\nrequirement for patients currently dependent on maintenance therapy\nwith oral corticosteroids. Updated references.\n7/2024 Annual review. Updated background with modified indication for\nCRSwNP. Specified existing prior authorization for under the medical\nbenefit. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n14"
  ]
}